Among these therapies, an immunotherapy targeting the PD-1/PD-Ls pathway would be considered as one of the most encouraging approaches because, in a Phase I clinical trial, treatment with PD-L1 antibody induced durable tumor regression and prolonged stabilization of disease in patients with advanced malignant cancers, including non-small-cell lung cancer, melanoma, and renal cell cancer [18]. The gene discussed is CD274; the disease is neoplasm.